Zheng Quan Ri Bao Wang·2026-01-29 11:08Core Viewpoint - Nuo Cheng Jian Hua Pharmaceutical Co., Ltd. expects significant revenue growth and profitability in 2025, driven by the commercialization of its products and global business development efforts [1] Financial Performance - The company anticipates revenue of approximately 2.37 billion yuan for 2025, representing a year-on-year increase of about 134% [1] - Nuo Cheng Jian Hua expects to achieve a net profit attributable to shareholders of around 630 million yuan in 2025, marking its first profit after losses [1] Product Development - The growth in revenue is attributed to the increasing sales of Obinutuzumab (brand name: Yinuokai) for marginal zone lymphoma (MZL) and the approval of new indications for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [1] - The company’s Tanxizumab (brand name: Mingnuokai) has become the first CD19 monoclonal antibody approved in China for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL), contributing to rapid growth in drug revenue for 2025 [1]